Indirect comparison of efficacy and safety between immune checkpoint inhibitors and antiangiogenic therapy in advanced non–small-cell lung cancer

• Published in: Scientific reports 2018-06, Vol.8 (1), p.9686-11, Article 9686
• Main Authors: Chen, Jin-Hua, Yang, Jia-Lian, Chou, Che-Yi, Wang, Jiun-Yi, Hung, Chin-Chuan
• Format: Article
• Language: English
• Subjects: 59; 631/67/1612/1350; 692/4028/67/1059/602; Angiogenesis Inhibitors - therapeutic use; Antibodies, Monoclonal - metabolism; Bevacizumab; Bevacizumab - therapeutic use; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - metabolism; Clinical trials; Humanities and Social Sciences; Humans; Immune checkpoint inhibitors; Lung cancer; Lung Neoplasms - drug therapy; Lung Neoplasms - metabolism; Monoclonal antibodies; multidisciplinary; Nivolumab - therapeutic use; Non-small cell lung carcinoma; Patients; PD-1 protein; Pembrolizumab; Platinum; Science; Science (multidisciplinary); Targeted cancer therapy; Toxicity
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-018-27994-x

In this study, we conducted an indirect comparison analysis to compare the efficacy and safety of immune checkpoint inhibitors with those of antiangiogenic therapy—two effective treatment methods for advanced non–small-cell lung cancer (NSCLC). Eligible randomised control trials of immune checkpoint inhibitors, antiangiogenic therapy, and doublet platinum-based therapy published up to July 2017 were comprehensively analysed. Through the indirect comparison analysis of 37 trials involving 16810 patients, treatments were compared for overall survival (OS) and grade 3–5 adverse events. For first-line treatment, the use of pembrolizumab alone (hazard ratio [HR]: 0.6; 95% confidence interval [CI]: 0.4–0.91) and a combination of bevacizumab and doublet platinum-based therapy (HR: 0.86; 95% CI: 0.75–0.99) demonstrated substantial survival benefits compared with doublet platinum-based therapy. For subsequent treatment, nivolumab may provide higher efficacy and lower toxicity than antiangiogenic therapy. Overall, anti-PD1 monoclonal antibodies may be superior to antiangiogenic therapy in terms of OS and grade 3–5 adverse events. This meta-analysis suggests that pembrolizumab and nivolumab might be favourable choices for first-line and subsequent treatment, respectively, for patients with advanced NSCLC. Additional randomised control trials are required for a comprehensive evaluation of the outcomes among regimens.